The company is jointly invested by investors from Laos, China and Canada, with a land area of 3 hectares and a total investment of USD 60 million, the pharmaceutical workshop is built with reference to the EU GMP standard, producing OTC finished pharmaceutical preparations and antitumor generic drugs. all of them will be put into operation in 2021, with an annual output value of up to USD 100 million.